Jasper Therapeutics (JSPR) Earnings Analysis
Jasper Therapeutics (JSPR) next reports earnings on 2026-08-12, consensus EPS -0.38 USD. Last quarter (2026-05-14) it beat with EPS -0.0612 USD vs -0.46 USD est (+86.7%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -0.22.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does JSPR next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -0.38 USD |
| Revenue estimate | n/a |
JSPR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -0.0612 USD | -0.46 USD | +86.7% | Beat |
| 2026-03-30 | -0.32 USD | -0.79 USD | +59.5% | Beat |
| 2025-11-10 | -1.13 USD | -1.01 USD | -11.9% | Miss |
| 2025-08-13 | -1.74 USD | -1.2 USD | -45% | Miss |
| 2025-05-12 | -1.41 USD | -1.17 USD | -20.5% | Miss |
| 2025-02-27 | -1.62 USD | -1.27 USD | -27.6% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
JSPR valuation and analyst view
| Trailing P/E | -0.22 |
|---|---|
| Trailing EPS | -2.90764 USD |
| Price / book | 4.20 |
| Dividend yield | 0.00% |
| Market cap | 0.01B |
| Analyst consensus | Buy (8 buy / 5 hold / 0 sell) |
| Avg price target | 3 USD |
Related research pages
Frequently asked questions
When is Jasper Therapeutics (JSPR)'s next earnings date?
Jasper Therapeutics is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.38 USD.
Did JSPR beat earnings last quarter?
In its 2026-05-14 report, JSPR posted EPS of -0.0612 USD versus a -0.46 USD estimate — a beat of 86.7%.
What is JSPR's earnings track record?
Over the last 6 reported quarters with consensus data, JSPR beat estimates 2 times (33%).
What is JSPR's current P/E ratio and EPS?
JSPR trades at a trailing P/E of -0.22 on trailing EPS of -2.907641911487361 USD.
What do analysts rate JSPR?
Analyst consensus is "Buy" across 13 ratings (0 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 3 USD.